Bloomberg reported yesterday that the French drug agency is pulling pioglitazone from the market in view of its recent association with bladder cancer. I mentioned this here May 14. Pioglitazone is sold in the U.S. as Actos. I don’t expect the U.S. Food and Drug Administration to follow suit soon.